Search results

  1. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

  2. Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults

  3. Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access (IPG710)

    Evidence-based recommendations on percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access in adults. This involves using

  4. Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when

  5. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    Recommendation ID NG161/1 Question Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and

  6. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    Recommendation ID NG191/8 Question What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab

  7. Is high-flow nasal oxygen effective in reducing breathlessness compared with standard care or conventional oxygen therapy for people in hospital with COVID-19 and respiratory failure when it is agreed that treatment will not be escalated beyond non-invasive respiratory support or palliative care is needed?

    Recommendation ID NG191/5 Question Is high-flow nasal oxygen effective in reducing breathlessness compared with standard care or conventional

  8. Looked-after children and young people (NG205)

    This guideline covers how organisations, practitioners and carers should work together to deliver high-quality care, stable placements and nurturing relationships for looked-after children and young people. It aims to help these children and young people reach their full potential and have the same opportunities as their peers.

  9. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and

  10. Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

    Evidence-based recommendations on berotralstat (Orladeyo) for preventing recurrent attacks of hereditary angioedema in people 12 years and older

  11. Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)

    Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chem

  12. The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register

    The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose,...

  13. Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

    Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years

  14. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults

  15. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (MTG60)

    Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography

  16. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.

  17. Evidence on the safety of laparoscopic removal of uterine fibroids with power morcellation shows potentially serious complications. In particular there is a risk of spreading undiagnosed malignant tissue, which has higher prevalence in people who are postmenopausal or over 50. Evidence on the procedure's efficacy is limited in quantity. Therefore, further research should report details of patient selection, surgical technique (including any containment system used) and long-term outcomes.

    Recommendation ID IPG703/1 Question Evidence on the safety of laparoscopic removal of uterine fibroids with power morcellation shows potentially

  18. Evidence on the safety of magnetic resonance therapy for knee osteoarthritis shows no major safety concerns. Evidence on efficacy is inadequate in quality and quantity and shows no benefit over placebo. Therefore, this procedure should not be used unless it is part of a research study. Further research should be in the form of appropriately powered randomised  controlled trials comparing the procedure with placebo. It should report patient  selection and treatment protocols, including the number of sessions and  magnetic field strength.

    Recommendation ID IPG702/1 Question Evidence on the safety of magnetic resonance therapy for knee osteoarthritis shows no major safety

  19. Interventions to improve CPAP adherence: Which interventions, including behavioural interventions, are most clinically and cost effective to improve adherence to CPAP in people with OSAHS, obesity hypoventilation syndrome (OHS) and COPD–OSAHS (chronic obstructive pulmonary disease–OSAHS) overlap syndrome who have difficulty using CPAP?

    Recommendation ID NG202/3 Question Interventions to improve CPAP adherence: Which interventions, including behavioural interventions, are